tbuckley/cabot-search huggingface dataset:
Activity of Anti-Tumor Endoribonucleases, Onconase (ranpirnase) and R-Amphinase in Chronic Lymphocytic Leukemia
Authors: Piotr Smolewski, Anna Linke-Szewczyk, Barbara Cebula, Kuslima Shogen, Wojciech Ardelt, Zbigniew Darzynkiewicz, Tadeusz Robak
Journal: Blood (2008)
Discovering the Epigenetic Modifications and the Alterations in Cellular DNA Damage Response Pathways That Drive Myelomagenesis; Clinical Implications Into the Biology of Multiple Myeloma
Authors: Maria Gkotzamanidou, Evangelos Terpos, Petros P. Sfikakis, Meletios Athanasios Dimopoulos, Vassilis L. Souliotis
Journal: Blood (2011)
AML with Recurrent Genetic Abnormalities and AML with Myelodysplasia-Related Changes Account for Three-Quarters of Previously Untreated Pediatric AML-the Results of a Nation-Wide Central Review in Japan-
Authors: Akitoshi Kinoshita, Hayato Miyachi, Hiromichi Matsushita, Tomohiko Taki, Miharu Yabe, Nobutaka Kiyokawa, Kiminori Terui, Hashii Yoshiko, Takao Deguchi, Hiroyuki Takahashi, Takashi Taga, Yasuhide Hayashi, Akio Tawa, Souichi Adachi, Masahito Tsurusawa, Keizo Horibe
Journal: Blood (2011)
Prevalence of Extramedullary Hematopoiesis, Vertebral, Hepatic and Splenic Hemangioma and Renal Cyst Among Thalassaemic Patients: A Retrospective Study from the Myocardial Iron in Thalassemia (MIOT) Network
Authors: Alessia Pepe, Antonella Meloni, Alessandra Briatico Vangosa, Fabrizia Terrazzino, Maria Giovanna Neri, Domenico Maddaloni, Gaetano Roccamo, Sabrina Armari, Aurelio Maggio, Cristina Salvatori, Vincenzo Positano, Paolo Ricchi
Journal: Blood (2015)
AB1101-HPR Quality of Life in Patient with Established Rheumatoid Arthritis: A Qualitative Study
Authors: K. Malm, A. Bremander, M.L.E. Andersson, S. Bergman, I. Larsson
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Fatigue, pain, stiffness and impaired physical function are some of the most pronounced symptoms in rheumatoid arthritis (RA) that may affect quality of life. Quality of life is an individual experience composed of a wide range of factors, including physical health, psychological state, level of independence, social relationships, and the patients9 relationship to salient features of their environment. There is a need to describe and assess quality of life in chronic diseases like established RA. Previous research has mainly focused on disease-specific instruments for assessing quality of life. A deeper understanding of patients9 experience of quality of life in established RA is important in both clinical research and daily clinical practice. <h3>Objectives</h3> To describe variations in patients9 experiences of quality of life in established RA <h3>Methods</h3> The study had a qualitative design with a phenomenographic approach, including 22 interviews with patients from the Swedish BARFOT (Better Anti-Rheumatic FarmacoTherapy) cohort, BARFOT, a long time follow up study of early RA. Patients were strategically selected by gender (14 women and 8 men), age (30 to 84 years old), disease duration (8–23 years), function as measured by HAQ (0–1.38), and quality of life as measured by EQ5D (0.52–1.00). The interviews were recorded, transcribed verbatim and coded into categories. <h3>Results</h3> Four categories emerged from the patients9 experiences of quality of life in established RA: well-being, freedom, empowerment, and participation. Quality of life as well-being meant pleasure and being physical active. Quality of life as freedom meant dependence or independence in the ability to manage daily life activities. Quality of life as empowerment meant different coping strategies, such as positive thinking and resources to manage fatigue, pain and physical function. Quality of life as participation meant togetherness in different contexts with other people. <h3>Conclusions</h3> Quality of life in established RA could be understood by the patients in different ways. The patients experienced quality of life as well-being, freedom, empowerment, and participation. This is important knowledge when evaluating the concept of quality of life in RA research, and for health professionals when promoting quality of life in patients with RA. <h3>Disclosure of Interest</h3> None declared
Abstract 1784: Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with <i>EGFR</i> mutations
Authors: Wee-Lee Yeo, Gregory J. Riely, Mark G. Kris, Daniel G. Tenen, William Pao, Susumu Kobayashi, Daniel B. Costa
Journal: Cancer Research (2010)

Abstract Introduction: The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are active in non-small-cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations. The usual clinical dose of gefitinib (250 mg/day) is only one third of its maximum tolerated dose (MTD), while the dose of erlotinib (150 mg/day) is at its MTD. In NSCLC cell lines both TKIs have similar micromolar (μM) inhibitory concentrations. We explored if erlotinib at 25 mg/day (presumed trough serum concentration similar to gefitinib 250 mg/day at around 0.5 μM) would be active in EGFR mutated NSCLC. Methods and Patients: To study inhibitory concentrations of gefitinib and erlotinib, we studied EGFR mutated cell lines (HCC827, H3255, PC-9, H1975) exposed to increasing concentrations of these TKIs. Further on, we performed a retrospective evaluation of seven patients with advanced EGFR mutated (exon 19 deletions and L858R) NSCLC that were given erlotinib at 25 mg daily as their first EGFR TKI. Results: In EGFR mutated cell lines, both gefitinib and erlotinib had median IC50 inhibitory concentrations with similar values and statistical correlation (Pearson r = 0.9999, p &amp;lt; 0.0001). Concordance between the IC50 of gefitinib and erlotinib was confirmed using a separate published dataset of 8 EGFR-mutant NSCLC lines (r = 0.9919, p &amp;lt; 0.0001). These results indicate that both EGFR inhibitors have similar inhibitory concentrations in EGFR mutated cells. Of the 7 patients treated with erlotinib 25 mg/day, 5 (71.5%) had partial radiographic responses. Median progression-free survival (PFS) was 17 months, and individual PFS exceeds 6 months in most patients that have received drug for at least that period. Toxicities were minimal with only 2 (28.5 %) patients having a rash (grade 1) and none (0%) experiencing diarrhea. Conclusions: In patients with EGFR activating mutations, a dose of erlotinib 25 mg/day leads to impressive response rate and PFS similar to the growing experience with gefitinib 250 mg/day and erlotinib 150 mg/day. Identifying prospectively the clinically-active dose ranges of erlotinib and gefitinib will help further personalize care for patients with tumors harboring EGFR mutations. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1784.
P263 Does the use of lactate improve the CURB-65 score in community acquired pneumonia patients admitted to a district general hospital?
Authors: TW Nicholson, S Connaire, V Kronsten, S Black, JES Park
Journal: Thorax (2016)

Community acquired pneumonia (CAP) is a leading cause of admission and mortality. CURB-65 is the traditional risk stratification score. This can under predict severity in the young and does not predict requirement for higher level care. Combining CURB-65 with lactate can improve this.<sup>1</sup> We reviewed CAP admissions over one month to determine if lactate improved risk stratification. CAP patients were identified via coding. Authors reviewed admission chest radiographs and reports to confirm CAP. CURB-65 score was calculated from the electronic patient record (EPR), and electronic discharge letters. Lactate values were identified from Emergency Department documents scanned into EPR. Accuracy of coding and mortality in a wrongly coded group was a secondary measurement. A LAC–CURB score of low, medium or high was allocated. 138 episodes of CAP were coded. 89 were confirmed CAP. Mean age was 71.2 yrs (21–98). CURB-65 score was available in 87. 45 scored CURB-65 0–1 with 2 deaths (4.4%). 24 were CURB-65 2, with 8 deaths (33.3%) and 6 of 18 CURB-65 3–5 patients died (33.3%). A lactate value was available in 52. 16 had a low LAC-CURB score with 0 deaths and 1 ICU admission. 23 had a medium score, with 3 deaths (13%) and 2 ICU admissions. 13 had a high LAC-CURB score, with 4 deaths (31%) and 1 ICU admission. In 4 patients it was the lactate value that increased the risk category from a medium CURB-65 score to a High LAC-CURB score. All 4 were admitted to ICU, with 2 deaths. Length of stay did not alter significantly with CURB-65 or LAC-CURB, but increased with severity. Diagnoses were available in 45 of the 49 patients coded incorrectly as CAP with a 17.78% mortality rate, identical to the CAP group. Mortality was higher for medium and high CURB-65 patients, but a difference between them was only seen when the LAC-CURB score was applied. A high lactate identified patients in the medium CURB-65 group who died or required higher level care. Patients wrongly coded as CAP also have a high mortality. <h3>Reference</h3> Chen YX. <i>Thorax</i> 2015;<b>70</b>(5).
Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM)
Authors: Xenofon Papanikolaou, Rashid Z Khan, Adam Rosenthal, Clyde Bailey, Yogesh Jethava, Christoph Heuck, Susan B. Panozzo, Maurizio Zangari, Frits van Rhee, Carolina Schinke, Faith E Davies, Gareth J Morgan, Bart Barlogie
Journal: Blood (2014)
ADAMTS13 Antigen, Activity, Autoantibody and ADAMTS13/fXI Complex Levels May Be Useful Diagnostic Biomarkers for Patients with Sickle Cell Disease.
Authors: Hugh J.L. Fryer, Nicholas Grafos, Enriqueta R. Guinto, Jogin Wu, Bing Bai, Robert S. Greenfield
Journal: Blood (2007)
Pericytes, an overlooked player in vascular pathobiology
Authors: David Ferland-McCollough, Sadie Slater, Jai Richard, Carlotta Reni, Giuseppe Mangialardi
Journal: Pharmacology & Therapeutics (2016)

Pericytes are a heterogeneous population of cells located in the blood vessel wall. They were first identified in the 19th century by Rouget, however their biological role and potential for drug targeting have taken time to be recognised. Isolation of pericytes from several different tissues has allowed a better phenotypic and functional characterization. These findings revealed a tissue-specific, multi-functional group of cells with multilineage potential. Given this emerging evidence, pericytes have acquired specific roles in pathobiological events in vascular diseases. In this review article, we will provide a compelling overview of the main diseases in which pericytes are involved, from well-established mechanisms to the latest findings. Pericyte involvement in diabetes and cancer will be discussed extensively. In the last part of the article we will review therapeutic approaches for these diseases in light of the recently acquired knowledge. To unravel pericyte-related vascular pathobiological events is pivotal not only for more tailored treatments of disease but also to establish pericytes as a therapeutic tool.
Phase 1b Evaluation of the Safety and Efficacy of a 30-Minute IV Infusion of Carfilzomib In Patients with Relapsed and/or Refractory Multiple Myeloma
Authors: Kyriakos Papadopoulos, David Samuel diCapua Siegel, Seema B. Singhal, Jeffrey R. Infante, Edward A. Sausville, Michael S. Gordon, Michael Kauffman, Tina Woo, Susan Lee, Lynne Bui, Alison L. Hannah, Peter Lee
Journal: Blood (2010)
Anti-Tumor Activity of Immunoproteasome Selective Inhibitors.
Authors: Francesco Parlati, Monette Aujay, Siv Lise Bedringaas, Susan Demo, Bjorn Gjertsen, Eileen Goldstein, Jing Jiang, Christopher Kirk, Guy Laidig, James Lorens, Yan Lu, David Micklem, Paulina Ruurs, Kevin Shenk, Catherine Sylvain, Congcong Sun, Tina Woo, Han-Jie Zhou, Mark Bennett
Journal: Blood (2007)
GvHD Kinetics after Haploidentical TK-Cells: In-Vivo HSV-TK Suicide Machinery Is Effective in GvHD Control and Provide a Long-Term Immune-Suppressive Treatment-Free Survival
Authors: Maria Teresa Lupo-Stanghellini, Chiara Bonini, Giacomo Oliveira, Attilio Bondanza, Luca Vago, Raffaella Greco, Jacopo Peccatori, Scialini Colombi, Antonio Lambiase, Fabio Ciceri, Claudio Bordignon
Journal: Blood (2014)
Array-CGH Identifies Regions, Including the FOXP1 Locus, Associated with Different Clinical Outcome in Diffuse Large B-Cell Lymphomas (DLBCL) Treated with R-CHOP
Authors: Marta Scandurra, Paola M.V. Rancoita, Timothy C. Greiner, Wing C. Chan, Julie M. Vose, Giorgio Inghirami, Annalisa Chiappella, Luca Baldini, Maurilio Ponzoni, Andres JM Ferreri, Santiago Montes-Moreno, Miguel A. Piris, Silvia Franceschetti, Gianluca Gaidano, Fabio Facchetti, Alessandra Tucci, Thierry Lazure, Olivier Lambotte, Silvia Uccella, Graziella Pinotti, Giancarlo Pruneri, Giovanni Martinelli, Josep Nomdedeu, Maria Grazia Tibiletti, Ekaterina Chigrinova, Cassio P. De Campos, Andrea Rinaldi, Emanuele Zucca, Ivo Kwee, Francesco Bertoni
Journal: Blood (2008)
Polymorphisms in Myeloid Cell Leukemia-1 and the Risk for Acute Myeloid Leukemia
Authors: Hee Nam Kim, Li Yu, Nan young Kim, Il-Kwon Lee, Yeo-Kyeoung Kim, Deok-Hwan Yang, Je-Jung Lee, Hee-je Kim, Woo-Sung Min, Moo-Rim Park, Deog-Yeon Jo, Jong-Ho Won, Jae-Yong Kwak, Hyeoung- Joon Kim
Journal: Blood (2008)
Whole-Exome Sequencing Identifies Novel Risk Variant for Thrombotic Storm
Authors: Thomas L. Ortel, Gary Beecham, Dale Hedges, Patrice Whitehead, Ashley Beecham, Susan Hahn, Janice W. Lawson, Doruk Erkan, Leonardo R. Brandao, Andra H. James, Marilyn J. Manco-Johnson, Roshni Kulkarni, Craig S. Kitchens, Margaret Pericak-Vance, Jeffery M Vance
Journal: Blood (2011)
Th17/Treg in Human Graft-Versus-Host-Disease (GvHD) of the Gastro-Intestinal (GI) Tract
Authors: Gerard Socie, Philippe Ratajczak, Christophe Leboeuf, Allisson Desveaux, Regis Peffault de Latour, Marie Robin, Jean Yves Mary, Anne Janin
Journal: Blood (2008)
Elevated Mitochondrial Membrane Potential in CLL Cells Is Associated with a more aggressive Natural History
Authors: Jeffrey R Gardner, Kristina Knapp, Mark G. Frattini, Nicole Lamanna, Renier Brentjens, Joseph G Jurcic, Peter G. Maslak, Ellin Berman, Mark Weiss, David A. Scheinberg, Mark Heaney
Journal: Blood (2011)
Decrease in Transfusion Needs in Patients with Higher-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Treated with 5-Azacytidine. a Retrospective Study
Authors: Panagiotis Theodorou Diamantopoulos, Konstantinos Zervakis, Athanasios G. Galanopoulos, Panagiotis Bakarakos, Vasiliki Papadopoulou, Theodoros Iliakis, Fani Kalala, Nefeli Giannakopoulou, Niki Rougala, Eleni Variami, Aglaia Dimitrakopoulou, Nora-Athina Viniou
Journal: Blood (2014)
Overexpression of BAALC Indicates Drug Resistance and Inferior Survival in Adult B-Precursor Acute Lymphoblastic Leukemia.
Authors: Andrea Kühnl, Nicola Gökbuget, Andrea Stroux, Thomas Burmeister, Martin Neumann, Sandra Heesch, Torsten Haferlach, Dieter Hoelzer, Wolf Karsten Hofmann, Eckhard Thiel, Claudia D Baldus
Journal: Blood (2009)
Transarterial Therapies for Hepatocellular Carcinoma
Authors: Ezio Lanza, Matteo Donadon, Dario Poretti, Vittorio Pedicini, Marco Tramarin, Massimo Roncalli, Hyungjin Rhee, Young Nyun Park, Guido Torzilli
Journal: Liver Cancer (2016)

&lt;b&gt;&lt;i&gt;Background:&lt;/i&gt;&lt;/b&gt; The treatment of hepatocellular carcinoma (HCC) is still a major health issue because of its increasing incidence and because of the complexity of its management. Transarterial embolization (TAE) and transarterial chemoembolization (TACE) are two widely used locoregional therapies in the treatment of HCC, especially for unresectable intermediate and advanced HCCs. &lt;b&gt;&lt;i&gt;Summary: &lt;/i&gt;&lt;/b&gt;The modern use of TAE and TACE opens new scenarios for the treatment of unresectable HCC and has yielded interesting results. The present work describes the role of transarterial therapies for HCC and focuses on the different Western and Eastern approaches to the study of response predictors. &lt;b&gt;&lt;i&gt;Key Messages: &lt;/i&gt;&lt;/b&gt;Recent refinements in interventional radiology techniques and in HCC patient selection have facilitated better local control of the disease. The molecular profiling of HCC to predict the response to TACE and TAE will greatly help clinicians identify the optimum therapy.
Thienopyridine-Associated Thrombotic Thrombocytopenia Purpura: Updated Antibody Results From the SERF-TTP Study.
Authors: Anaadriana Zakarija, Thanh Ha Luu, Hau C. Kwaan, June McKoy, Ivy Weiss, Paul Yarnold, Nicholas Bandarenko, Charles L. Bennett
Journal: Blood (2009)
Effectiveness of Defibrotide in the Prevention of VOD Among Patients Receiving Allogeneic Hematopoetic Cell Transplantation: A Retrospective Single Center Experience
Authors: Emre Tekgunduz, Seval Akpinar, Sinem Civriz Bozdag, Aysegul Tetik, Serife Kocubaba, Murat Cinarsoy, Gamze Durgun, Sinem Namdaroglu, Omür Kayikci, Bilge Ugur, Itir Sirinoglu Demiriz, Fevzi Altuntas
Journal: Blood (2012)
ATIM-35. RESULTS OF THE PHASE IB KEYNOTE-028 MULTI-COHORT TRIAL OF PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH RECURRENT PD-L1-POSITIVE GLIOBLASTOMA MULTIFORME (GBM)
Authors: David A. Reardon, Tae-Min Kim, Jean-Sebastien Frenel, Armando Santoro, Juanita Lopez, Deepa S. Subramaniam, Lillian L. Siu, Jordi Rodon, Kenji Tamura, Sanatan Saraf, Anne Morosky, Karen Stein, Jean-Charles Soria
Journal: Neuro-Oncology (2016)

Patients with recurrent GBM have limited treatment options and poor clinical outcome. Tumors, including GBM, use the PD-1 pathway to evade immune responses. KEYNOTE-028 (NCT02054806) evaluated the safety and efficacy of the anti–PD-1 monoclonal antibody pembrolizumab in 20 advanced solid tumor types. Results of the GBM cohort (N=26) are presented. Key inclusion criteria included advanced (unresectable and/or metastatic) bevacizumab-naive GBM, failure of or inability to receive standard therapy, ECOG PS 0-1, and PD-L1 expression in ≥1% of tumor or stroma cells by immunohistochemistry. Patients received pembrolizumab 10 mg/kg every 2 weeks for up to 24 months or until confirmed progression, intolerable toxicity, death, withdrawal of consent, or physician decision. Response was assessed every 8 weeks for the first 6 months and every 12 weeks thereafter. The primary end point was ORR per RECIST v1.1 by investigator review. Median age was 55.5 years; 53.8% were male; 53.8% had an ECOG PS of 1; all had received prior chemotherapy. As of the February 17, 2016, data cutoff date, median follow-up duration was 60.9 weeks (range, 11.7-94.0) and 22 (84.6%) patients had discontinued pembrolizumab. Treatment-related AEs occurred in 19 (73.1%) patients, most commonly fatigue and rash (n=6 each, 23.1%). Four (15.4%) patients experienced grade 3-4 treatment-related AEs (lymphopenia, type 2 diabetes mellitus, arthritis, and syncope). No patients died or discontinued pembrolizumab because of a treatment-related AE. There was 1 partial response (n=25; ORR, 4.0% [95% CI, 0.1-20.4]); an additional 12 (48.0%) patients experienced stable disease (SD). Median duration of SD was 39.4 weeks (range, 7.1+-85.9+). Median PFS was 2.8 months (95% CI, 1.9-9.1); median OS was 14.4 months (95% CI, 10.3-not reached). Treatment with pembrolizumab monotherapy was associated with a manageable safety profile, and consistent with that of other PD-1 agents, promising antitumor activity in patients with recurrent GBM.
Identification of Poor Risk Patients in Low and Intermediate-1 (Int-1) IPSS MDS with the New Ipssr Index and Comparison with Other Prognostic Indexes. A Study by the Spanish Group of MDS (GESMD)
Authors: David Valcárcel, Guillermo Sanz, Margarita Ortega, Benet Nomdedeu, Elisa Luño, María Diez-Campelo, M. Teresa Ardanaz, Carmen Pedro, Julia Montoro, Rosa Collado, Rafa Andreu, Victor Marco, Maria Teresa Cedena, Raquel de Paz, Mar Tormo, Blanca Xicoy, Fernando Ramos, Joan Bargay, Bernardo Gonzalez, Salut Brunet, Juan Antonio MuÃ±oz, Valle Gomez, Alicia Bailen, Joaquin Sanchez, Teresa Vallespi
Journal: Blood (2012)
Collagen Fibers Structure Detected By Second-Harmonic Generation Microscopy: A Potential Prognostic Marker for High-Risk Nodular Sclerosis
Authors: Guilherme Rossi Assis de Mendonça, Rodrigo de Andrade Natal, Bruna de Albuquerque Murbach, Marcia Torresan Delamain, Carmino Antônio De Souza, Carlos Lenz Cesar, Jose Vassallo
Journal: Blood (2015)
High Dose Cytosine Arabinoside (HD-AraC) vs Standard Dose AraC (SD-AraC) during Induction, and Stem Cell Transplantation Followed by IL-2 or No Maintenance in Acute Myelogenous Leukemia (AML): First Report on the AML-12 Phase III Trial of the EORTC-Leukemia Group (LG) and GIMEMA.
Authors: Roelof Willemze, Stefan Suciu, Franco Mandelli, Theo de Witte, Boris Labar, Jean-Pierre Marie, Giovanna Meloni, Martin Mistrik, Francois Lefrere, Vincenzo Liso, Meral Beksac, Salvatore Mirto, Zwi Berneman, Antonio Peta, Dominik Selleslag, Andrea Camera, Xavier Thomas, Dominique Bron, Jose Eduardo Guimaraes, Georges Fillet, Petra Muus, Caroline Gilotay, Paola Fazi, Liliana Baila, Marco Vignetti, Sergio Amadori
Journal: Blood (2005)
P0107 : Reduced abundance of mineralocorticoid receptor in cirrhosis: a mechanism that is linked to hypoxia and proinflammatoric cytokines
Authors: A. Wolf, B. Schreier, S. Mildenberger, S. Pohl, S. Rabe, A. Thonig, M. Gekle, A. Zipprich
Journal: Journal of Hepatology (2015)
Development of Bortezomib Induced Peripheral Neuropathy (BiPN) In Multiple Myeloma: Incidence and Molecular Characterization In Newly Diagnosed Patients Treated with Bortezomib
Authors: Annemiek Broyl, Sophie Corthals, Joost L.M. Jongen, Bronno van der Holt, Rowan Kuiper, Yvonne de Knegt, Laila el Jarari, Uta Bertsch, Henk Lokhorst, Brian GM Durie, Hartmut Goldschmidt, Pieter Sonneveld
Journal: Blood (2010)
Transfection of Dendritic Cells with In Vitro Transcribed RNA Induces Polyclonal CMV-Specific CD8+ and CD4+ Mediated T Cell Responses.
Authors: Annkristin Heine, Tobias Holderried, Frank Grünebach, Silke Appel, Markus M. Weck, Volker L. Reichardt, Peter Brossart
Journal: Blood (2004)
Isoprostane (8-Epiprostaglandin F2α) Plasma Concentration and Aspirin Resistance in Patients after Ischaemic Stroke.
Authors: Krystyna M. Zawilska, Marcin M. Zytkiewicz, Ewelina E. Hanszke, Zofia Z. Turowiecka, Liwia L. Gielwanowska, Piotr P. Psuja
Journal: Blood (2007)
Response Adapted Lenalidomide Based Therapy For Newly Diagnosed (ND) Standard Risk Older Adults With Multiple Myeloma (MM): An International Collaboration
Authors: Rachid Baz, Hui-Yi Lin, Sung-Soo Yoon, Kihyun Kim, Melissa Alsina, Kenneth H. Shain, Dan Sullivan, Hye Jin Kang, Jin Seok Kim, Cheolwon Suh, Je-Jung Lee, Jeong-A Kim, Yang Soo Kim, Chang-Ki Min, Jae-Yong Kwak, Sung-Hyun Kim, Won Sik Lee, Junshik Hong, Jae Hoon Lee
Journal: Blood (2013)
Second Transplants in Relapsed Multiple Myeloma (MM): Autologous (AHCT) Versus Non-Myeloablative/Reduced Intensity (NST/RIC) Allogeneic Transplantation (AlloHCT)
Authors: Cesar O. Freytes, David H. Vesole, Xiaobo Zhong, Jennifer Le-Rademacher, Angela Dispenzieri, Sagar Lonial, Gustavo Milone, Parameswaran Hari
Journal: Blood (2011)
Alterations of DCC Gene in B-Cell Malignancies.
Authors: Hisao Nagoshi, Tomohiko Taki, Kazuhiro Nishida, Minako Goto, Satoru Kobayashi, Yasuhiko Tsutsumi, Yosuke Matsumoto, Junya Kuroda, Shigeo Horiike, Takemi Otsuki, Masafumi Taniwaki
Journal: Blood (2009)
α-Enolase From Injured Patients and Stored Packed Red Blood Cells Activates Pulmonary Endothelium and Serves as the First Event In a Two-Event Model of Neutrophil Cytotoxicity
Authors: Nicole Tucker, Monika Dzieciatkowska, Kirk Hansen, Samina Khan, Marguerite Kelher, Anirban Banerjee, Ernest Moore, Christopher C Silliman
Journal: Blood (2010)
Presence of Isocitrate Dehydrogenase (IDH) Mutations May Predict Clinical Response to Hypomethylating Agents in Patients with Acute Myeloid Leukemia (AML)
Authors: Elizabeth A. Griffiths, Brandon Carter-Cooper, Seda Tolu, Laurie A Ford, Rena G. Lapidus, Meir Wetzler, Eunice S. Wang, Arash Etemadi, Ashkan Emadi
Journal: Blood (2014)